Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 380

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers

Open access
Haas, Andrew R., Tanyi, Janos L., O’Hara, Mark H., Gladney, Whitney L., Lacey, Simon F., Torigian, Drew A., Soulen, Michael C., Tian, Lifeng, McGarvey, Maureen, Nelson, Anne Marie, Farabaugh, Caitlin S., Moon, Edmund, Levine, Bruce L., Melenhorst, J. Joseph, Plesa, Gabriela, June, Carl H., Albelda, Steven M., Beatty, Gregory L.·2019·Molecular Therapy

Abstract

This phase I study investigated the safety and activity of lentiviral-transduced chimeric antigen receptor (CAR)-modified autologous T cells redirected against mesothelin (CART-meso) in patients with malignant pleural mesothelioma, ovarian carcinoma, and pancreatic ductal adenocarcinoma. Fifteen patients with chemotherapy-refractory cancer (n = 5 per indication) were treated with a single CART-meso cell infusion. CART-meso cells were engineered by lentiviral transduction with a construct composed of the anti-mesothelin single-chain variable fragment derived from the mouse monoclonal antibody SS1 fused to intracellular signaling domains of 4-1BB and CD3zeta. Patients received 1–3 × 10 7 or 1–3 × 10 8 CART-meso cells/m 2 with or without 1.5 g/m 2 cyclophosphamide. Lentiviral-transduced CART-meso cells were well tolerated; one dose-limiting toxicity (grade 4, sepsis) occurred at 1–3 × 10 7 /m 2 CART-meso without cyclophosphamide. The best overall response was stable disease (11/15 patients). CART-meso cells expanded in the blood and reached peak levels by days 6–14 but persisted transiently. Cyclophosphamide pre-treatment enhanced CART-meso expansion but did not improve persistence beyond 28 days. CART-meso DNA was detected in 7/10 tumor biopsies. Human anti-chimeric antibodies (HACA) were detected in the blood of 8/14 patients. CART-meso cells were well tolerated and expanded in the blood of all patients but showed limited clinical activity. Studies evaluating a fully human anti-mesothelin CAR are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2019.07.015

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 380

Metadata

Authors
Haas, A. R., Tanyi, J. L., O’Hara, M. H., Gladney, W. L., Lacey, S. F., Torigian, D. A., Soulen, M. C., Tian, L., McGarvey, M., Nelson, A. M., Farabaugh, C. S., Moon, E., Levine, B. L., Melenhorst, J. J., Plesa, G., June, C. H., Albelda, S. M., & Beatty, G. L.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2019-11
Volume
27
Issue
11
Pages
1919-1929
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2965330503
Cited by
380
References
47
FWCI
13.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. https://app.cochat.ai/papers/10.1016/j.ymthe.2019.07.015
The paper
Haas, A. R., Tanyi, J. L., O’Hara, M. H., Gladney, W. L., Lacey, S. F., Torigian, D. A., Soulen, M. C., Tian, L., McGarvey, M., Nelson, A. M., Farabaugh, C. S., Moon, E., Levine, B. L., Melenhorst, J. J., Plesa, G., June, C. H., Albelda, S. M., & Beatty, G. L. (2019). Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2019.07.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.